Ranger Investment Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.7M Sell
2,115,417
-168,393
-7% -$1.54M 1.12% 37
2026
Q1
$20.6M Sell
2,283,810
-17,095
-0.7% -$270K 1.49% 29
2025
Q4
$42M Sell
2,300,905
-39,825
-2% -$671K 2.88% 3
2025
Q3
$34.3M Sell
2,340,730
-49,645
-2% -$851K 2.39% 5
2025
Q2
$43.5M Buy
2,390,375
+786,865
+49% +$16M 3.04% 4
2025
Q1
$31.8M Buy
+1,603,510
New +$27.7M 2.27% 13

Other funds holding ADMA

Ranger Investment Management's ADMA Position: Q2 2026 in Review

Ranger Investment Management reduced its ADMA Biologics (ADMA) stake by 7.4% in Q2 2026, selling an estimated $1.54M and leaving 2,115,417 shares worth $17.7M. The position accounts for 1.12% of the portfolio, ranked #37.

Ranger Investment Management first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $43.5M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Ranger Investment Management held 2,115,417 shares of ADMA Biologics worth $17.7M as of Q2 2026.
  • Ranger Investment Management sold 168,393 ADMA Biologics shares in Q2 2026, an estimated $1.54M.
  • ADMA Biologics made up 1.12% of Ranger Investment Management's portfolio in Q2 2026, its #37 holding.
  • Ranger Investment Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
  • Ranger Investment Management's ADMA Biologics position peaked at $43.5M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ranger Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.